Evaluation of the Therapeutic Effect of Azacytidine Combined with Vene-toclax in the Treatment of Elderly Myeloid Leukemia
Objective To investigate the feasibility of azacitidine plus Venacela in the treatment of elderly myeloid leukemia.Methods From August 2019 to August 2023,a total of 80 patients with elderly myeloid leukemia in the De-partment of Hematology,Guiping People's Hospital were unrandomly selected.They were divided into two groups:the control group(n=40,treated with azacitidine alone)and the study group(n=40,treated with azacytidine combined with venetoclax)by difference treatment.The effective rate,blood biochemical index,adverse reaction rate and quality of life score were compared.Results The effective rate of treatment in the study group was 90.00%,higher than that in the control group(72.50%),the difference was statistically significant(χ2=4.021,P<0.05).The platelet count,white blood cell count,and hemoglobin concentration in the study group were higher than those in the control group,and the proportion of bone marrow primitive cells was lower than those in the control group,the differences were statistically significant(all P<0.05).The incidence of adverse reactions in the study group was 5.00%,lower than that in the con-trol group(20.00%),the difference was statistically significant(χ2=4.114,P<0.05).Conclusion In elderly patients with myeloid leukemia,the combination therapy of azacitidine and vinacrine can improve their blood biochemical indica-tors,reduce the occurrence of adverse reactions,and improve treatment effectiveness.
NETL
NSTL
万方数据
